ClinicalTrials.gg
CompletedNCT01879371Updated Nov 16, 2016Results posted

Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate

A Phase 1 interventional study of Ibuprofen+caffeine FDC and Ibuprofen (Nurofen Immedia®) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-16.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To investigate the relative bioavailability of ibuprofen from a (FDC) film-coated tablet of ibuprofen and caffeine vs. a tablet of ibuprofen (Brufen®) and a tablet of ibuprofen lysinate (Nurofen Immedia®).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects
  • Age 18 to 50 years
  • (BMI) 18.5 to 29.9 kg/m2
  • Subjects must be able to understand and comply with study requirements

Exclusion criteria

Exclusion criteria:

  • Any relevant deviation from healthy conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Ibuprofen (Brufen®)

    film-coated tablet

    Drug: Ibuprofen (Brufen®)

  • Active comparator
    Ibuprofen (Nurofen Immedia®)

    film-coated tablet

    Drug: Ibuprofen (Nurofen Immedia®)

  • Experimental
    Ibuprofen+caffeine

    fixed-dose-combination (FDC)

    Drug: Ibuprofen+caffeine FDC

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-tz)

    AUC(0-tz): area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 to the last quantifiable data point

    Time frame: 2 hours (h) before drug administration and 5minutes (min), 10min, 15min, 30min, 45min, 1h, 1h 15min, 1h 30min, 1h 45min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h after drug administration

  2. Cmax

    Cmax: maximum measured concentration of Ibuprofen in plasma

    Time frame: 2 hours (h) before drug administration and 5minutes (min), 10min, 15min, 30min, 45min, 1h, 1h 15min, 1h 30min, 1h 45min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h after drug administration

Secondary outcomes

  1. AUC(0-inf)

    AUC(0-inf): area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

    Time frame: 2 hours (h) before drug administration and 5minutes (min), 10min, 15min, 30min, 45min, 1h, 1h 15min, 1h 30min, 1h 45min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h after drug administration

07

Results

Posted Nov 16, 2016

Participant flow

36 healthy male and female subjects (at least a third of each sex) were recruited from the volunteers' pool of the Human Pharmacology centre of BI Pharma GmbH \& Co. KG, Ingelheim, Germany.

Participant flow — Overall Study
MilestoneIbu + Caf / Ibu Acid / Ibu LysinateIbu + Caf / Ibu Lysinate / Ibu AcidIbu Acid / Ibu Lysinate/ Ibu + CafIbu Acid/ Ibu + Caf / Ibu LysinateIbu Lysinate/ Ibu + Caf / Ibu AcidIbu Lysinate / Ibu Acid / Ibu + Caf
Started666666
Completed666666
Not completed000000

Outcome measures

PrimaryAUC(0-tz)

AUC(0-tz): area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 to the last quantifiable data point

Time frame:
2 hours (h) before drug administration and 5minutes (min), 10min, 15min, 30min, 45min, 1h, 1h 15min, 1h 30min, 1h 45min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h after drug administration
Reported as:
Geometric mean · μg*h/mL
AUC(0-tz)
μg*h/mLIbuprofen + Caffeine (FDC) TabletIbuprofen Acid Film-coated TabletIbuprofen Lysinate Film-coated Tablet
AUC(0-tz)133 ± 22.2124 ± 19.4122 ± 19.3
Statistical analysis
  • Ibuprofen + Caffeine (FDC) Tablet vs Ibuprofen Acid Film-coated Tablet · Geometric mean ratio (net): 107.85 · 90% CI 105.334 to 110.431The geometric mean ratio is calculated as the geometric mean of 'Ibuprofen + Caffeine (FDC) tablet ' divided by the geometric mean of ' Ibuprofen acid film-coated tablet '.
  • Ibuprofen + Caffeine (FDC) Tablet vs Ibuprofen Lysinate Film-coated Tablet · Geometric mean ratio (net): 109.48 · 90% CI 107.072 to 111.936The geometric mean ratio is calculated as the geometric mean of 'Ibuprofen + Caffeine (FDC) tablet ' divided by the geometric mean of ' Ibuprofen lysinate film-coated tablet '.
PrimaryCmax

Cmax: maximum measured concentration of Ibuprofen in plasma

Time frame:
2 hours (h) before drug administration and 5minutes (min), 10min, 15min, 30min, 45min, 1h, 1h 15min, 1h 30min, 1h 45min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h after drug administration
Reported as:
Geometric mean · μg/mL
Cmax
μg/mLIbuprofen + Caffeine (FDC) TabletIbuprofen Acid Film-coated TabletIbuprofen Lysinate Film-coated Tablet
Cmax31.0 ± 17.231.1 ± 22.544.0 ± 20.6
Statistical analysis
  • Ibuprofen + Caffeine (FDC) Tablet vs Ibuprofen Acid Film-coated Tablet · Geometric mean ratio (net): 99.65 · 90% CI 93.874 to 105.776The geometric mean ratio is calculated as the geometric mean of 'Ibuprofen + Caffeine (FDC) tablet ' divided by the geometric mean of ' Ibuprofen acid film-coated tablet '.
  • Ibuprofen + Caffeine (FDC) Tablet vs Ibuprofen Lysinate Film-coated Tablet · Geometric mean ratio (net): 70.42 · 90% CI 67.087 to 73.928The geometric mean ratio is calculated as the geometric mean of 'Ibuprofen + Caffeine (FDC) tablet ' divided by the geometric mean of ' Ibuprofen lysinate film-coated tablet '.
SecondaryAUC(0-inf)

AUC(0-inf): area under the concentration-time curve of Ibuprofen in plasma over the time interval from 0 extrapolated to infinity

Time frame:
2 hours (h) before drug administration and 5minutes (min), 10min, 15min, 30min, 45min, 1h, 1h 15min, 1h 30min, 1h 45min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h after drug administration
Reported as:
Geometric mean · μg*h/mL
AUC(0-inf)
μg*h/mLIbuprofen + Caffeine (FDC) TabletIbuprofen Acid Film-coated TabletIbuprofen Lysinate Film-coated Tablet
AUC(0-inf)135 ± 21.7127 ± 20.1125 ± 20.2
Statistical analysis
  • Ibuprofen + Caffeine (FDC) Tablet vs Ibuprofen Acid Film-coated Tablet · Geometric mean ratio (net): 106.50 · 90% CI 104.050 to 109.004The geometric mean ratio is calculated as the geometric mean of 'Ibuprofen + Caffeine (FDC) tablet ' divided by the geometric mean of ' Ibuprofen acid film-coated tablet '.
  • Ibuprofen + Caffeine (FDC) Tablet vs Ibuprofen Lysinate Film-coated Tablet · Geometric mean ratio (net): 108.59 · 90% CI 106.185 to 111.054The geometric mean ratio is calculated as the geometric mean of 'Ibuprofen + Caffeine (FDC) tablet ' divided by the geometric mean of ' Ibuprofen lysinate film-coated tablet '.

Adverse events

Collected over from up to 21 days prior to first drug administration until 30 days after end of trial, 64 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen + Caffeine (FDC) Tablet—0/36 (0%)2/36 (5.6%)
Ibuprofen Acid Film-coated Tablet—0/36 (0%)4/36 (11.1%)
Ibuprofen Lysinate Film-coated Tablet—0/36 (0%)1/36 (2.8%)
Most frequent other events
Most frequent other events
EventIbuprofen + Caffeine (FDC) TabletIbuprofen Acid Film-coated TabletIbuprofen Lysinate Film-coated Tablet
HeadacheNervous system disorders2/364/361/36

Baseline characteristics

Treated Set (TS): included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Ibu + Caf / Ibu Acid / Ibu LysinateIbu + Caf / Ibu Lysinate / Ibu AcidIbu Acid / Ibu Lysinate/ Ibu + CafIbu Acid/ Ibu + Caf / Ibu LysinateIbu Lysinate/ Ibu + Caf / Ibu AcidIbu Lysinate / Ibu Acid / Ibu + CafTotal
Mean38.7 ± 7.636.3 ± 3.342.8 ± 4.540.2 ± 3.837.5 ± 9.238.3 ± 7.139.0 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)Ibu + Caf / Ibu Acid / Ibu LysinateIbu + Caf / Ibu Lysinate / Ibu AcidIbu Acid / Ibu Lysinate/ Ibu + CafIbu Acid/ Ibu + Caf / Ibu LysinateIbu Lysinate/ Ibu + Caf / Ibu AcidIbu Lysinate / Ibu Acid / Ibu + CafTotal
Female44322015
Male22344621
08

Study locations

1 site
  • 1335.2.1 Boehringer Ingelheim Investigational Site
    Ingelheim, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2013
First posted
Jun 17, 2013
Start
Jun 2013
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Nov 16, 2016
Last update
Nov 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01879371
Responsible party
Sponsor
First posted
Jun 17, 2013
Start date
Jun 2013
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Nov 16, 2016
Last update
Nov 16, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Caffeine

Start the discussion